Experimental combo targets genetic weakness in aggressive blood cancers
NCT ID NCT07646821
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests adding ropeginterferon alfa-2b to the standard drug azacitidine for people newly diagnosed with a type of blood cancer (MDS or AML) that has a specific genetic change called a TP53 mutation. The goal is to find the safest dose of the combination and see if it can help control the disease. The trial enrolls about 30 adults and tracks side effects and disease response.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
ropeginterferon alfa-2b and azacitidine
What this could lead to
If successful, this combination could offer a new treatment option for people with a hard-to-treat form of blood cancer.
What could go wrong
This is an early-phase trial with only 30 participants, so the benefits are uncertain. Side effects from the drug combination are possible.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MDS/AML are added.
By submitting, you agree to our Terms of use
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
MD Anderson Cancer Center
Houston, Texas, 77030, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••